NEWS & MEDIA

Image Alt Text

NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS WHICH ALLOWS TO PROCEED WITH THE CLINICAL DEVELOPMENT INTO PHASE III

THE BIOLOGICAL OBJECTIVE AND THREE OUT OF FOUR CLINICAL OBJECTIVES WERE MET:

  • Highly statistically significant efficacy in reduction of interferon signature
  • Lack of statistically significant clinical efficacy measured by BICLA[1]score
  • Statistical trend on clinical efficacy measured by SRI-4[2]  with reduction of steroid less than or equal to 5mg/day
  • Statistically significant clinical efficacy on the LLDAS[3] score
  • Favorable safety profile of IFNalpha Kinoid treatment

 

Read More

Neovacs and Centurion Pharma continue their collaboration in...

Paris and Boston, December 11th 2018 – 7:30 am CET – Neovacs (Euronext Growth Paris: ALNEV), leader in the field of...

NEOVACS ANNOUNCES THE CONTINUATION OF THE DEVELOPMENT OF ITS...

Paris and Boston, the 11th of October 2018 – 07:00 AM CEST- Neovacs (Euronext Growth Paris ALNEV), leader in...

NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS...

Paris and Boston, 11 September 2018 – 07H00am CEST- Neovacs (Euronext Growth Paris ALNEV), leader in active...

NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR...

THE BIOLOGICAL OBJECTIVE AND THREE OUT OF FOUR CLINICAL OBJECTIVES WERE MET:

NEOVACS STRENGTHENS INTELLECTUAL PROPERTY POSITION IN EUROPE...

Newly issued patent covers IFNalpha Kinoid and its application in all diseases related to an overproduction of...

NEOVACS PROVIDES CORPORATE UPDATE AND REPORTS FULL-YEAR 2017...

Paris, March 30, 2018, 7:30 am CEST  – NEOVACS (Euronext Growth Paris: ALNEV), a leader in active...

NEOVACS’ ANNOUNCES THE SUCCESS OF ITS GENERAL MEETING OF...

Paris and Boston, March 12, 2018 – 6.00 pm CET – Neovacs (Euronext Growth Paris: ALNEV), a leader in...

Neovacs Announces Positive Data Review from Last IDSMB Review...

Final Trial Results Expected in June 2018   Paris and Boston, February 13th 2018, 07:00 am CET – Neovacs...

NEOVACS STRENGTHENED ITS INTELLECTUAL PROPERTY IN RUSSIA...

 This patent covers IFNalpha kinoid and its application in all diseases related to an overproduction of...